Satoshi Shimada
Tohoku University
5 Papers
11 Citations
Satoshi Shimada is an academic researcher from Tohoku University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease
Koichi Kikuchi,Daisuke Saigusa,Yoshitomi Kanemitsu,Yotaro Matsumoto,Paxton Thanai,Naoto Suzuki,Koki Mise,Hiroaki Yamaguchi,Tomohiro Nakamura,Kei Asaji,Chikahisa Mukawa,Hiroki Tsukamoto,Toshihiro Sato,Yoshitsugu Oikawa,Tomoyuki Iwasaki,Yuji Oe,Tomoya Tsukimi,Noriko N. Fukuda,Hsin Jung Ho,Fumika Nanto-Hara,Jiro Ogura,Ritsumi Saito,Shizuko Nagao,Yusuke Ohsaki,Satoshi Shimada,Takehiro Suzuki,Takafumi Toyohara,Eikan Mishima,Hisato Shima,Yasutoshi Akiyama,Yukako Akiyama,Mariko Ichijo,Tetsuro Matsuhashi,Akihiro Matsuo,Yoshiaki Ogata,Ching Chin Yang,Chitose Suzuki,Matthew C. Breeggemann,Jurgen Heymann,Miho Shimizu,Susumu Ogawa,Nobuyuki Takahashi,Takashi Suzuki,Yuji Owada,Shigeo Kure,Nariyasu Mano,Tomoyoshi Soga,Takashi Wada,Jeffrey B. Kopp,Shinji Fukuda,Atsushi Hozawa,Masayuki Yamamoto,Sadayoshi Ito,Jun Wada,Yoshihisa Tomioka,Takaaki Abe +55 more
TL;DR: It is shown that phenol sulfate, a gut microbiota-derived metabolite, is increased in diabetic kidney disease and contributes to the pathology by promoting kidney injury, suggesting phenyl sulfate could be used a marker and therapeutic target for the treatment of diabetic kidneys disease.
Pathophysiological and molecular mechanisms involved in renal congestion in a novel rat model
Satoshi Shimada,Takuo Hirose,Takuo Hirose,Chika Takahashi,Emiko Sato,Satoshi Kinugasa,Satoshi Kinugasa,Yusuke Ohsaki,Kiyomi Kisu,Hiroshi Sato,Sadayoshi Ito,Takefumi Mori,Takefumi Mori +12 more
TL;DR: A rat renal congestion model was created and Transgelin and platelet-derived growth factor receptors, as indicators of pericyte-myofibroblast transition, were upregulated in the pericytes and the adjacent interstitium, which could result in extracellular matrix expansion and tubular injury in renal congestion.
Role of Chronic Use of Tolvaptan in Patients with Heart Failure Undergoing Peritoneal Dialysis.
Takefumi Mori,Naho Kurasawa,Yusuke Ohsaki,Kenji Koizumi,Shinichi Sato,Shinichi Sato,Ikuko Oba-Yabana,Ikuko Oba-Yabana,Satoshi Shimada,Emiko Sato,Eri Naganuma,Mihoko Tsuchikawa,Sadayoshi Ito +12 more
- 01 Jan 2016
TL;DR: Chronic tolvaptan treatment has a beneficial role in body fluid control without a reduction in cardiac and renal function and volume control depends on an equal reduction in ECW and ICW, which can also have a benefit in avoiding hyponatremia.
6
Concurrent isolated IgG2-positive membranous nephropathy and malignant B-cell lymphoma
Satoshi Shimada,Takashi Nakamichi,Gen Yamada,Kaori Narumi,Hajime Usubuchi,Tae Yamamoto,Satoshi Ichikawa,Noriko Fukuhara,Mariko Miyazaki,Hideo Harigae,Hiroshi Sato,Sadayoshi Ito +11 more
TL;DR: It is, thus, necessary to consider hematological malignancy when a diagnosis of MN is made and further studies are expected to elucidate the pathogenesis and to help establish the adequate treatment for this rare situation.
Efficacy and Biocompatibility of Neutral Icodextrin Peritoneal Dialysis Fluid.
Satoshi Shimada,Takefumi Mori,Takefumi Mori,Kenji Koizumi,Shinichi Sato,Shinichi Sato,Ikuko Oba-Yabana,Ikuko Oba-Yabana,Yusuke Ohsaki,Emiko Sato,Eri Naganuma,Naho Kurasawa,Mihoko Tsuchikawa,Sadayoshi Ito +13 more
- 01 Jan 2016
TL;DR: Water and solute removal with the new n-ICO is not much different from that with a-ICO, however, biocompatibility as reflected by cell proliferation was superior undern-ICO than under a- ICO and equal to proliferation under glucose PD fluid.
1